Katsuaki Maehara

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

Katsuaki Maehara
Aug 19, 2024, 11:57 | Insight
Katsuaki Maehara: Interesting indirect comparison analysis for Melanoma
Katsuaki Maehara shared a post on X: "Melanoma Journal of Clinical Oncology. NCCN Guidelines recommended both…
Aug 14, 2024, 07:04 | Insight
ES-SCLC 5-year survival outcomes inIMpower133 and IMbrella study
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X, about recent paper…
Aug 13, 2024, 11:55 | Blog
Katsuaki Maehara: Uncommon EGFR Mutations and the variability in therapeutic efficacy
Katsuaki Maehara, Director of Medical Education Colleagues shared a post on X: "Uncommon EGFR mutations…
Aug 10, 2024, 13:45 | Insight
Katsuaki Maehara: EGFR mutated NSCLC
Katsuaki Maehara, Director of Medical Education Colleagues shared a post on X: “EGFR mutated NSCLC.…
Aug 8, 2024, 03:46 | Blog
Katsuaki Maehara: Importance of Sin3a in the stable expression of Foxp3 in Tregs
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X, about recent paper…
Aug 5, 2024, 07:03 | Insight
Katsuaki Maehara: Removal of ICIs resistance by CAF-derived TSG-6 inhibition
Katsuaki Maehara, Cancer Biologist, shared a post on X: "Removal of ICIs resistance by CAF-derived…
Jul 28, 2024, 10:33 | Insight
Katsuaki Maehara: New histopathologic indices to predict postoperative recurrence of lung cancer
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X about a recent…
Jul 14, 2024, 07:21 | Drugs
Drug list Ver 3 for mNSCLC: 1st line EGFR common mutations
Katsuaki Maehara, Director of Medical Education Colleagues, shared on X: "Lung - NSCLC Drug list…
Jun 29, 2024, 07:45 | Insight
Katsuaki Maehara: The changes in TME and TKI treatment resistance by EGFR and ALK TKI
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X:       …
May 22, 2024, 00:34 | Insight
Katsuaki Maehara: NSCLC updated
Katsuaki Maehara, Director of Medical Education Colleagues shared a post on X: "NCCN Guidelines updated.…
Apr 5, 2024, 17:48 | Blog
Katsuaki Maehara: Updated Oncology Drug List, Ver.2
Katsuaki Maehara, Director of Medical Education Colleagues, posted the following on X: “Updated Oncology Drug…
Feb 2, 2024, 12:30 | Blog
Katsuaki Maehara: I have compiled a list of NSCLC drugs for 2024
Katsuaki Maehara, Director of Medical Education Colleagues, posted the following on X: "NSCLC Drug List…
Dec 31, 2023, 20:07 | Blog
Katsuaki Maehara: Patritumab Deruxtecan (HER3-DXd) clinical trial transition
Katsuaki Maehara, Director of Medical Education Colleagues, recently shared a post by EGFR Resisters on X/Twitter,…
Dec 23, 2023, 03:25 | Drugs
Katsuaki Maehara: Therapeutic development of 4th generation TKIs is active for acquired resistance to osimelnitinib for C797
Katsuaki Maehara, Director of Medical Education Colleagues, recently shared the following on X/Twitter: "Therapeutic development…
Dec 5, 2023, 18:49 | Blog
Katsuaki Maehara: Stage Ⅳ EGFRm NSCLC - Sequential Treatment Options
Katsuaki Maehara, Director of Medical Education Colleagues, recently shared the following on Twitter: "Stage Ⅳ…
Nov 11, 2023, 17:08 | Blog
Katsuaki Maehara: Great article about ADCs by Paolo Tarantino
Katsuaki Maehara, Director of Medical Education Colleagues, recently shared the following on X/Twitter: "Great article…
All: 16 Posts: 1 - 100
Special Coverage